FTRE
Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.42
−0.31%Year over year
Reported trailing growth
- Revenue
- -2.1%
- EBITDA
- +109.5%
- EBIT
- +101.8%
- EPS
- +91.9%
- Free cash flow
- +246.1%
- Operating cash flow
- +308.0%
Forward estimates
Based on analyst estimates
- Revenue
- +2.1%
- EBITDA
- +218.2%
- EPS
- +209.3%
Three-year CAGR
- Revenue
- -1.4%
- EBITDA
- —
- EBIT
- +81.1%
- Net income
- —
- EPS
- —
- Free cash flow
- +46.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026